Skip to main content

. 1988 Sep 24;297(6651):772–773. doi: 10.1136/bmj.297.6651.772

Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.

A R Morton ¹, J A Cantrill ¹, G V Pillai ¹, A McMahon ¹, D C Anderson ¹, A Howell ¹

PMCID: PMC1834406 PMID: 3142542

772

Images in this article

p772-a
on p.772

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Ibbotson K. J., Harrod J., Gowen M., D'Souza S., Smith D. D., Winkler M. E., Derynck R., Mundy G. R. Human recombinant transforming growth factor alpha stimulates bone resorption and inhibits formation in vitro. Proc Natl Acad Sci U S A. 1986 Apr;83(7):2228–2232. doi: 10.1073/pnas.83.7.2228. [DOI] [PMC free article] [PubMed] [Google Scholar]
Pfeilschifter J., D'Souza S. M., Mundy G. R. Effects of transforming growth factor-beta on osteoblastic osteosarcoma cells. Endocrinology. 1987 Jul;121(1):212–218. doi: 10.1210/endo-121-1-212. [DOI] [PubMed] [Google Scholar]
Pons-Anicet D. M., Krebs B. P., Mira R., Namer M. Value of CA 15:3 in the follow-up of breast cancer patients. Br J Cancer. 1987 May;55(5):567–569. doi: 10.1038/bjc.1987.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
van Holten-Verzantvoort A. T., Bijvoet O. L., Cleton F. J., Hermans J., Kroon H. M., Harinck H. I., Vermey P., Elte J. W., Neijt J. P., Beex L. V. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet. 1987 Oct 31;2(8566):983–985. doi: 10.1016/s0140-6736(87)92555-4. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES